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Abstract (word count 221) 1 
BACKGROUND: Pharmacists are in demand now more than ever to provide high-quality expertise 2 
about the effectiveness, safety and use of medications. Amidst an increasingly complex and costly 3 
healthcare system, policy makers need robust evidence to justify public spending on pharmacy 4 
services. Research on the impact of existing and emerging pharmacy practices are required. 5 
 6 
OBJECTIVE: To explore barriers and opportunities to enhance research among pharmacists in Ireland 7 
utilising a World Café methodology. 8 
 9 
METHODS: A pharmacy research discussion day was held in November 2018, open to all pharmacists 10 
in Ireland. A World Café methodology was utilised as a mechanism to facilitate group discussions 11 
about pharmacy practice research. 12 
 13 
RESULTS: Discussions with 63 attendees identified four themes and seventeen subthemes. The four 14 
themes were challenges undertaking research, research motivations, leadership, and training. 15 
Subthemes included robust evidence, clinical, economic and societal outcomes, alignment with 16 
national and international health system priorities, need for incentives from professional training 17 
bodies, competitive business model and embed within schools of pharmacy. 18 
 19 
CONCLUSIONS: The most commonly discussed barriers inhibiting research were workload, 20 
technology limitations and financial considerations. Organisational leadership to prioritise and 21 
coordinate research efforts, training to build research capacity, building on existing examples of 22 
excellence and initiation of bottom up community-based research projects were identified in our study 23 
as opportunities to enhance pharmacist involvement in research and ultimately patient health 24 
outcomes. 25 
 26 
Keywords: Pharmacy practice research, Leadership, Pharmacist research, World Café, Pharmacy 27 
research.  28 
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1. Introduction 29 
The role of the patient-facing pharmacist in 2020 has shifted away from the preparation of various 30 
medicaments and their own nostrums to meet patient demand for high quality information about the 31 
effectiveness, safety and use of pharmaceuticals. Pharmaceuticals cost the health service in Ireland 32 
€2.8bn in 2017(1), a figure which has continued to rise over the last 5 years. In addition, adverse 33 
effects from medication are common, largely preventable and (sometimes) clinically harmful, and 34 
therefore medications and medication-related morbidity present an increasing cost burden on our 35 
health care system. This combined with shifts in population whereby people live longer with 36 
multimorbidity has resulted in the emergence of new fields of pharmacy practice, with a focus on: 37 
clinical therapeutics, evidence based medicine, pharmacoeconomics and patient care(2). Although 38 
there are many subspecialties within pharmacy, clinical roles that rely on these new skills make up the 39 
vast majority of pharmacist employment(3). 40 
 Canada, Australia, the United States of America and the United Kingdom (UK) have 41 
repositioned the pharmacist within their health systems, including the introduction of pharmacist 42 
prescribing, emerging opportunities in general practice (GP), and other advanced pharmacist 43 
practitioner roles(4–6). Ireland currently lags behind and career options for graduating pharmacists 44 
remain similar to those seen over a decade ago. This could perhaps be explained by the unclear 45 
leadership structure of pharmacy in Ireland. In contrast to the countries listed above, there are multiple 46 
organisations in Ireland who are involved in driving and creating pharmacy healthcare policy, with 47 
each representing different, diverse groups within the pharmacy profession. There is no clear unifying 48 
organisation to represent all pharmacists across traditional and non-traditional occupations. 49 
In Ireland (and indeed globally), recent government policies are encouraging patient centred 50 
care, which presents an opportunity for pharmacists to contribute to enhanced care. However, for 51 
policy makers to justify spending public funds on the development of a service, robust evidence is 52 
required. Pharmacist involvement in health services research is needed to assess the feasibility and 53 
value of new pharmacy services and roles. 54 
Robust research has often preceded practice development. Indeed, the unique perspective of 55 
the pharmacist in clinical medicine was perhaps first recognised in the early 1960s when Levy, 56 
Riegelman and others published a series of articles in journals such as the New England Journal of 57 
Medicine(7–11) which at that time, rarely (if ever) saw contributions from pharmacists(7–11). This 58 
work helped consolidate the impact of formulation on therapeutic efficacy, and indeed, the pharmacist 59 
as the expert on formulation. The concept of robust research has been illustrated previously(12–16) 60 
and will not be explored in this work. 61 
Research activity of pharmacists has been investigated previously and time constraints and 62 
the risk averse nature of the profession are often cited to explain this lack of research activity(17,18). 63 
This work seeks to To explore barriers and opportunities to enhance research among pharmacists in 64 
Ireland utilsing a World Café methodology. 65 
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2. Methods 66 
2.1. Setting and design 67 
A Pharmacy Practice Research Discussion day was held in Dublin, Ireland in November 2018 to 68 
facilitate discussion of these issues. The event was organised by the authors in coordination with the 69 
staff of the Irish Institute of Pharmacy to explore barriers and opportunities to enhance research among 70 
pharmacists in Ireland. This event was advertised as an open invitation on the Irish Institute of 71 
Pharmacy newsletter which is distributed to every pharmacist in Ireland (in 2018, 6220 pharmacists). 72 
The event was free of charge for attendees and included panel discussions on health system 73 
requirements and the importance of practice based research, and brief (one minute) presentations from 74 
each attendee on their research interests. The final session of the day was a facilitated workshop on 75 
“How we can optimise our efforts” in relation to pharmacy practice research. This article describes 76 
the discussions from the workshop with the aim of encouraging further conversations about how to 77 
develop pharmacy research in Ireland. 78 
The discussions during the facilitated workshop were conducted using a World Café approach 79 
(19). The World Café has emerged as a novel modality to stimulate collaborative research(19–22). 80 
This approach assumes that the experts are already in the room and encourages creative thinking to 81 
provide solutions to the questions posed(20). It was for this reason that this methodology was selected; 82 
enabling participants to explore complexity (within their own profession) through conversation as 83 
pharmacists often do in their daily practice. The attendees were asked to randomly mix around the 84 
room and were then asked to consider the first World Café question and again reshuffled before 85 
considering the next question. Three questions were devised to enable discussions which would 86 
identify key issues or priorities relating to pharmacy practice research (PPR) and to stimulate debate 87 
around how these might be addressed (box 1). Each group had between 5-8 members and was 88 
facilitated by one of the event’s organisers (identified at the beginning of the World Café) who 89 
documented the discussions and sought feedback from the attendees on their views regarding the topic 90 
of discussion. The world café session lasted approximately two hours. 91 
1. What do we need from pharmacy practice research? 
2. What specific steps should we take to progress Irish Pharmacy Research? 
3. What is needed to enable the steps we’ve discussed in previous sessions? 
Box  1 – World Café questions 92 
2.2. Data collection and analysis 93 
Discussions from each group were captured in written format by a member of the research team and 94 
verbal feedback was also provided to wider audience from each group on each question, which was 95 
captured by video. The videos and written feedback were analysed to identify key themes. 96 
All data was independently coded by three members of the research team by identifying 97 
comments from the videos and written responses. All attendees were aware that responses were being 98 
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recorded and could opt-out of this if they wished. This was determined at the beginning of the day. 99 
Video recordings were uploaded to a private (password protected) site to allow any participant who 100 
opted-in to view and reflect on the discussions of the day. The team compared and discussed their 101 
findings to generate a set of codes which were divided into emergent themes and subthemes using a 102 
constant comparative method. The themes were then presented to the research team, then revised and 103 
reconstructed iteratively until a final set of themes emerged. 104 
 105 
2.3. Ethics statement 106 
Due to the anonymised nature of the reflections herein, this work carries little to no risk to participants. 107 
No ethical approval was sought to hold the World Café. After the event, we contacted participants to 108 
make them aware that we were going to write up a reflection of the event for publication. The writing 109 
does not identify or compare the contributions of individual attendees and great care was taken to 110 
maintain the right of all participants to confidentiality, including secure data storage. 111 
 112 
3. Results 113 
3.1. Attendees 114 
Of the 6220 pharmacists emailed, there were 63 attendees (1% participation rate) from a mixture of 115 
backgrounds including academia/research (n=41, 37%), community pharmacy (n=28, 25%), hospital 116 
pharmacy (n= 24, 22%), administrative (n=9, 8%) and other roles, including locum, teacher 117 
practitioner and superintendent pharmacist (n=9, 8%) (some selected more than one practice area). 118 
Attendees were notified after the event that the proceedings would be written up. 119 
 120 
3.2. Themes 121 
The three questions yielded 4 central themes: (1) challenges undertaking research, (2) research 122 
motivations, (3) leadership, coordination and prioritisation and (4) training and education with 17 123 
subthemes across these categories summarised in table 1. 124 
 125 
3.2.1. Challenges Undertaking Research 126 
It was recognized that although many pharmacists are actively doing research, some attendees 127 
expressed the view that it may be conducted in an ad-hoc fashion and the work often remains 128 
unpublished. Attendees identified the need for robust data and expressed a desire to improve research 129 
quality. There was concern that collecting robust data would be an onerous task and such activity 130 
would not be possible within a busy pharmacy. Many expressed that the practice of pharmacy is a full-131 
time job in itself and perhaps it is unreasonable to expect a pharmacist to perform his/her duties and 132 
conduct high-quality research to the standard required.  133 
One group reflected, that increased collaboration between academia and practice based 134 
pharmacists could be a fruitful solution. This increased collaboration would also give practitioners an 135 
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opportunity to influence the pharmacy student curriculum and serve as role models for the latest phase 136 
of new graduates which could enable the sharing of important practical information, via mentorship. 137 
One group suggested that research modules could be added to popular pharmacy dispensing 138 
software to facilitate data collection as part of routine daily practice. Further, pharmacists should be 139 
taught how to integrate data collection strategies into daily practice (i.e. coding prescriptions with a 140 
unique identifier) to facilitate research. 141 
A key challenge to the pharmacy profession is that although research conducted may have 142 
benefits for patients and society, there are commercial realities within community pharmacy that must 143 
be considered. Attendees suggested pharmacists may be reticent to invest in research as it rarely 144 
produced commercial benefit and any innovations in practice could be adopted by competitors who 145 
had not contributed to these developments. 146 
Across the groups there was a number of comments relating to a perceived lack of funding for 147 
PPR. It was felt that it is currently difficult to compete for funding particularly as medical and nursing 148 
colleagues have well established research cultures resulting from national and international 149 
frameworks coupled with strong links between academia and clinical practitioners. 150 
 151 
3.2.2. Research motivations 152 
Attendees discussed carrying out research to generate robust evidence on the process of care in a 153 
pharmacy setting with a specific focus on patient outcomes, harm reduction measurements, cost 154 
effectiveness, clinical effectiveness, patient safety and impacts on public health. It was noted that 155 
appropriate clinical, economic and societal outcomes were important in order to carry out meaningful 156 
research. Allied to that, many people expressed a desire to focus on the unique contributions of 157 
pharmacists to patient care when designing research projects. 158 
Attendees identified the need to ensure research activities are of a high quality. The PINCER 159 
cluster randomised trial(23) of a pharmacist interventions was used as an example of the type of robust 160 
research design to aim for. It was felt that research needs to have measurable benefits and interventions 161 
that were scalable would be important. Replicating studies at multiple pharmacy sites was also seen 162 
as important to generate robust evidence for interventions. 163 
The benefits of taking a multidisciplinary approach to research was discussed and attendees 164 
were keen to engage with doctors, practice nurses, physicians’ associates and pharmacy technicians. 165 
Furthermore, it would be paramount to extend these collaborations to include methodological experts, 166 
the advantages of which has been studied in great detail in the literature(24–27). Attendees also felt 167 
that research offered an opportunity to explore the value of pharmacists in healthcare delivery. In 168 
particular, they felt that research would allow pharmacists to document innovative practices, explore 169 
unanswered questions about the profession and communicate the value of pharmacists. The link 170 
between pride and empowerment of pharmacists and the need to document professional activities via 171 
research publications was also highlighted. 172 
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Pharmacy-led research in community or hospital settings was also seen as a way to promote 173 
best practice, which in turn may benefit the overall standard of pharmacy practice. Attendees observed 174 
how meaningful research is facilitating the development of specialisations within pharmacy e.g. 175 
prescriber role in some countries and emerging specialisations in hospital setting. 176 
The communication of research to non-academic audience via social media was seen as an 177 
important stage of research. The importance of communicating the benefits of research to pharmacy 178 
practitioners in the community was seen as a way to encourage increased participation of practitioners 179 
in research. It was felt that researchers could also work to improve how they communicate the benefits 180 
of research to the wider profession and the public. 181 
Attendees discussed the need to have research that leads to actionable outputs that feed into 182 
the Irish healthcare system. This led to a discussion about the value of two-way communication 183 
between research and policy. Research was seen as both informing policy and also implementing new 184 
policies and emerging health system priorities. 185 
 186 
3.2.3. Leadership, coordination and prioritization 187 
The importance of a coordinated and cohesive approach for developing PPR in order to yield the 188 
greatest potential benefit was discussed. Identifying areas of greatest need would be helpful so that 189 
resources could be targeted. This could be achieved by identifying three or four tangible goals to 190 
produce actionable outputs that could contribute to or form the basis for policy. It was highlighted that 191 
there should be an awareness and understanding of policies and priorities (nationally and 192 
internationally) and linkage of research to these so that projects could feed into the bigger picture and 193 
drive the pharmacy policy agenda. A means of achieving this would be increasing pharmacist 194 
involvement in policy working groups and clinical programmes. 195 
 It was recognised that organisations may pursue different and potentially opposing or 196 
divergent goals (e.g. a pharmacy business may wish to develop a revenue generating service while the 197 
government may wish to reduce costs), allocating tasks, roles and responsibilities, and putting 198 
structures in place for parties to come together to identify mutual goals and activities were mentioned 199 
as key to maximising research impact, and ensuring sustainability. A key structure to coordinate this 200 
would be some type of leadership body. While existing organisations, such as the Irish Institute of 201 
Pharmacy, Affiliation for Pharmacy Practice Experiential Learning (APPEL), and schools of 202 
pharmacy were identified as having a role, a specific body, such as a College of Pharmacy Practice or 203 
Faculty of Medicines Management was proposed. Such a body could provide direction, develop an 204 
agenda, support coordination and prioritisation of research activities, and ensure good governance. 205 
This body could also have a role in providing or facilitating training and accrediting sites and 206 
pharmacists as “research ready”. One question to be resolved was how such a body would be funded, 207 




3.2.4. Training and education  210 
Attendees discussed capacity-building and skills in relation to research. The willingness of 211 
pharmacists in practice, e.g. community and hospital settings, to contribute to practice research was 212 
highlighted, but that a lack of experience and knowledge of research may hinder this involvement. It 213 
was suggested this could be addressed by standards, in terms of research conduct, and that there was 214 
a need for training to develop skills to facilitate involvement. A further need identified was educating 215 
the profession regarding the benefits of research and research involvement, in order to drive 216 
participation.  217 
Training and skills development at a range of career levels (undergraduate, postgraduate, and 218 
continuing education) and using different modes (how-to guides, online modules, virtual learning 219 
environments, workshops, training fellowships, and higher degrees) were discussed. A number of 220 
existing training resources were identified which could be leveraged to address this need. As well as 221 
identifying what existing tools are available, it was felt that it is also important to identify what is 222 
lacking, in terms of resources, and in terms of the skill set of pharmacists generally. It was suggested 223 
that a repository of training resources could be hosted by the Irish Institute of Pharmacy. 224 
For the practicing pharmacist who wants to be involved, training should address how to do 225 
research, and could demystify research conduct (for example, what a principal investigator is, data 226 
management and governance, and other aspects of good research practice). This could feed into the 227 
development of research-ready pharmacy practice sites and pharmacists, and training could form the 228 
basis of accreditation of these sites, much like what occurs with training placement providers for 229 
pharmacy students. The importance of ensuring that front-line pharmacists are aware of research ethics 230 
such as obtaining consent and ensuring patient confidentiality and access to ethics committees or 231 
formation of an additional ethics committee was suggested. 232 
It was felt that research training and skills development should start with students as well as 233 
recent graduates. Attendees highlighted that while the undergraduate curriculum does address 234 
research, it is important for this to continue in a pragmatic way i.e. including student involvement and 235 
experience in research and the development practical skills. While undergraduate training in research 236 
provides a basis, alignment between undergraduate, postgraduate, and continuing education was 237 
highlighted as important. 238 
Attendees discussed the benefits of cooperation and collaboration, particularly engagement 239 
between students, universities, student placement providers, and pharmacists more broadly. For 240 
example, this could involve multi-site research studies, practicing pharmacists inputting on the topics 241 
for student research projects, and matching students and placement providers with common research 242 
interests to produce more meaningful research. The importance of cooperation with other healthcare 243 
professionalsin research was also highlighted, and that a major facilitator of this was inter-professional 244 
education at undergraduate level. This helps to develop a respect and understanding for the different 245 
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roles and skills across professions which would provide a solid foundation for collaborative inter-246 
professional work and research. 247 
 248 
4. Discussion 249 
The most commonly discussed barriers inhibiting research were workload, technology limitations and 250 
financial considerations. The potential of organisational leadership to prioritise and coordinate 251 
research efforts and facilitate training to build research capacity was also highlighted. This could be 252 
realised by building on existing examples of excellence in academic pharmacy and initiation of bottom 253 
up community-based research projects, as well as collaborations with well-established research 254 
networks with methodological expertise to enhance pharmacist involvement in research and ultimately 255 
patient health outcomes. 256 
 257 
4.1. Strengths and limitations 258 
The use the World Café methodology is a novel and highly effective method to provide evidence to 259 
stimulate national and international conversation on this important topic. While the invitation to this 260 
event was circulated to all registered pharmacists, academic and research roles were over-261 
represented among attendees, and we acknowledge the likely implicit research positive bias. The 262 
views of non-research active pharmacists should be sought. The attendees were homogenous in being 263 
limited to pharmacists, and neither other pharmacy-based roles (i.e. pharmacy technicians) or other 264 
health and social care professions were represented. While the focus on Ireland allowed the unique 265 
challenges within this health system to be examined, the discussions did not consider the development 266 
of pharmacy practice research internationally.  267 
 268 
4.2. Addressing challenges in undertaking research 269 
The most commonly discussed barriers inhibiting practice research were workload, Information 270 
Communication Technology (ICT) and financial considerations. Although these barriers have been 271 
reported previously for pharmacists(28–30) and other healthcare professionals(31) these studies 272 
identified that the establishment of research networks which enable collaborations between academia 273 
and clinicians could support pharmacist participation. Further, one study suggested that when 274 
pharmacists believe a project has intrinsic value they tend to be more willing to invest time, even in 275 
the absence of financial compensation(32). Participants at the World Café highlighted that economic 276 
justification of research is often necessary in the context of private businesses, particularly for 277 
community pharmacies. 278 
As healthcare is currently undergoing a digital transformation(33), pharmacists recognised the 279 
essential role ICT should play in the development of pharmacy practice research. A comprehensive 280 
publication by Beck et al. explores the pathways to bridge the gap between healthcare and research 281 
9 
 
using ICT(34). Specifically, incorporating data collection methods into our current ICT systems to 282 
generate data for research.  283 
 284 
4.3. Promoting engagement in research 285 
It is evident that there is a clear appetite amongst pharmacists to conduct pharmacy practice research. 286 
The benefit of the pharmaceutical perspective has been illustrated in geriatrics(35,36),  polypharmacy 287 
and deprescribing(35–37) and again across a range of disease states(38,39). This work has coincided 288 
with the firm establishment of the pharmacist within teams tackling these conditions. In addition to 289 
helping form professional identity(40), collaborative, multidisciplinary research has enabled practice 290 
based pharmacists to showcase their contributions to the health system(41–43).  291 
Recent work in other jurisdictions has explored how to support pharmacists taking the first 292 
steps towards research activity(44,45) and the Royal Pharmaceutical Society have outlined their idea 293 
of what ‘research ready’ means(46). In addition, the co-production model of delivering and improving  294 
public services through partnerships between the people using the services, clinicians and researchers 295 
strongly promotes the involvement of pharmacists in research as stakeholders(47). Under this model, 296 
the commitment of pharmacists to upskill in research methodology is less important and the emphasis 297 
is on contributing from their experience as practitioners. It is imperative that we encourage this 298 
intrinsic motivation and create opportunities for pharmacists to come together with other healthcare 299 
disciplines in frontline patient facing settings to undertake research. 300 
 301 
4.4. Leadership, coordination and prioritisation 302 
Strong leadership been linked to research success(48–50). Our discussions on the day focused on 303 
leadership at an organisational level. Similarly, a recent paper by Dolovich et al. setting goals for the 304 
development of the profession of pharmacy in Canada, identified organisational change and better 305 
external relationships as two key priorities for improving the future of pharmacy(2). 306 
Discussions regarding organisational leadership likely emerged as there is no formal 307 
professional body to support the pharmacy profession in Ireland. Despite this, there are pockets of 308 
research excellence throughout the country(51–60). These range from individual community 309 
pharmacists to hospitals to third level institutions. We can learn from these bright spots. While 310 
individuals and teams could provide leadership by example, the need for national coordination and 311 
leadership in Ireland was a theme that appeared during discussions throughout the World Café. 312 
Many attendees made reference to the split of the regulatory and advocacy functions of the 313 
Royal Pharmaceutical Society of Great Britain. The new Royal Pharmaceutical Society supports the 314 
development of research in the UK with their faculty programme, advanced pharmacy framework and 315 
guidance and support resources. Other models for this exist both nationally (Irish College of General 316 
Practitioners) and internationally (American Pharmacists Association (APhA)). The establishment of 317 
a research network is another commonly implemented model which has demonstrated success within 318 
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pharmacy(61–63) and other professions(64). A white paper from the APhA Foundation explored what 319 
leadership might look like within a PPR network detailing how a volunteer vs. leader directed model 320 
might function(65).  321 
 322 
4.5. Training and education 323 
Lack of research capacity was also highlighted as a significant challenge facing pharmacists. Cooke 324 
has explored how we might approach research capacity building in healthcare environments and her 325 
six principles of capacity building such as supporting research close to practice, developing 326 
infrastructure and encouraging partnerships and collaborations is a useful model that could be 327 
adopted(66). It was also clear from the discussions that there are repositories of learning resources 328 
available which could be shared to build foundational research skills. 329 
 In the literature, a Canadian study highlighted ways in which advanced practice could be 330 
achieved within the context of new Pharm.D. programmes. Namely, by incorporation of new teaching 331 
strategies, increased inter-professional education and a greater focus on experiential learning to 332 
establish strong mentorship links(67). Independently, Ireland has embraced these ideals with the 333 
introduction of experiential learning placements within the new 5-year pharmacy programme – 334 
facilitated by the Affiliation for Pharmacy Practice Experiential Learning (APPEL) group. Further, 335 
the Northern Ireland Centre for Pharmacy Learning and Development (NICPLD) has developed a 336 
Foundation Programme which specifies the development of skills around gathering and analysing 337 
information in addition to research and evaluation as key competencies. Further, the Health Research 338 
Board’s Clinician Scientist programme or its Applied Partnership Award also present as opportunities 339 
for all healthcare professions to engage in applied research. Perhaps these programmes need to be 340 
promoted or reinforced with additional funding to meet the training needs of pharmacists with an 341 
increased focus on research skills.  342 
During the emergence of Pharm.D. programs some commentators noted that these programs 343 
might not be suitable for all pharmacists(68,69). Indeed, as it requires significant investment of 344 
resources and time to develop a competent researcher it may be realistic to develop only some research 345 
ready pharmacists and pharmacies(68,69).  346 
 347 
5. Conclusions 348 
In 1981 Gerhard Levy wrote, “I believe sincerely that pharmacy is on the threshold of either a great 349 
and exciting future or mediocrity and oblivion. Much will depend on how future pharmacists are 350 
educated and trained.”(68) Perhaps pharmacy in Ireland is at another one of these crossroads and 351 
pharmacists urgently need to look beyond day to day operations or the profession may face a slow 352 
decline into irrelevance. 353 
It was evident from the discussion day that there is a clear appetite amongst pharmacists to 354 
collaborate with peers and across disciplines to conduct pharmacy practice research and build research 355 
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skills. Lack of prioritisation of issues and coordination of research issues was highlighted. This has 356 
led to an environment whereby pharmacy has been reactive rather than proactive to new technology 357 
and workforce planning(70). Indeed, many of the discussions were centred around the lack of a formal 358 
professional body to support the pharmacy profession in Ireland. This leads us to a number of 359 
questions; what will leadership look like in Irish pharmacy? Do we need new structures (or perhaps 360 
none at all), or do we need to reconfigure existing frameworks? These questions can only be answered 361 
by the profession, and answers need to be sought urgently. We recommend a collaborative approach, 362 
with pharmacists engaging more within the profession and connecting with external stakeholders to 363 
stimulate pharmacy research and take meaningful steps forward to enhance pharmacy practice. 364 
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Competitive business model 
Difficult to compete with other healthcare professionals for funding 





Clinical, economic and societal outcomes 
Collaborative approach 
Bottom up initiation of research projects 
 
Leadership Coordination of research activities 
Alignment with national and international policies and research themes 
Research prioritisation 
Need incentives from professional training bodies e.g. funding 
 
Training Embed within schools of pharmacy 
Share existing research training materials 
Meeting data governance and data protection requirements 
Start when students 
 Carry out research and dissemination across all levels 
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